We are live on ! Find out more

375 hedge funds and large institutions have $5.84B invested in ResMed in 2016 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 137 increasing their positions, 137 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 22

6% more capital invested

Capital invested by funds: $5.5B → $5.84B (+$332M)

4% more funds holding

Funds holding: 362375 (+13)

1.97% more ownership

Funds ownership: 61.98%63.95% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

0% more repeat investments, than reductions

Existing positions increased: 137 | Existing positions reduced: 137

19% less call options, than puts

Call options by funds: $17.3M | Put options by funds: $21.5M

Holders
375
Holders Change
+13
Holders Change %
+3.59%
% of All Funds
9.98%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
38
Increased
137
Reduced
137
Closed
22
Calls
$17.3M
Puts
$21.5M
Net Calls
-$4.16M
Net Calls Change
-$8.37M

RMD Hedge Fund Activity: Q3 2016 in Review

375 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q3 2016, worth a combined $5.84B — up 6% from $5.5B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new RMD positions and 22 closed out — a net gain of 16 holders — while 137 added to existing stakes and 137 trimmed.

The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $343M. The largest seller was Fidelity Investments, cutting an estimated $113M.

  • 375 institutional investors held ResMed (RMD) as of Q3 2016, up from 362 in Q2 2016.
  • Funds reported $5.84B of ResMed stock for Q3 2016, up 6% quarter-over-quarter.
  • 38 funds opened new ResMed positions in Q3 2016 and 22 closed out, a net change of +16 holders.
  • The largest ResMed buyer in Q3 2016 was Baillie Gifford & Co, an estimated $343M added.
  • The largest ResMed seller in Q3 2016 was Fidelity Investments, an estimated $113M sold.

Based on aggregated 13F filings for Q3 2016.